Clinical Trials
Renal Cell Cancer


A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avemumab (MSB0010718C) In combination with Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy In the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma.

EMR 100070-008

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.


A Phase1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (Bladder, Colon,Gastric,Renal) .


A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718c) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction .